Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells.
Anthracyclines (such as doxorubicin or daunorubicin) are among the most effective anticancer drugs, but their usefulness is hampered by the risk of irreversible cardiotoxicity. Dexrazoxane (ICRF-187) is the only clinically approved cardioprotective agent against anthracycline cardiotoxicity. Its act...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2013-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3792022?pdf=render |
| _version_ | 1818909849672482816 |
|---|---|
| author | Anna Vavrova Hana Jansova Eliska Mackova Miloslav Machacek Pavlina Haskova Lucie Tichotova Martin Sterba Tomas Simunek |
| author_facet | Anna Vavrova Hana Jansova Eliska Mackova Miloslav Machacek Pavlina Haskova Lucie Tichotova Martin Sterba Tomas Simunek |
| author_sort | Anna Vavrova |
| collection | DOAJ |
| description | Anthracyclines (such as doxorubicin or daunorubicin) are among the most effective anticancer drugs, but their usefulness is hampered by the risk of irreversible cardiotoxicity. Dexrazoxane (ICRF-187) is the only clinically approved cardioprotective agent against anthracycline cardiotoxicity. Its activity has traditionally been attributed to the iron-chelating effects of its metabolite with subsequent protection from oxidative stress. However, dexrazoxane is also a catalytic inhibitor of topoisomerase II (TOP2). Therefore, we examined whether dexrazoxane and two other TOP2 catalytic inhibitors, namely sobuzoxane (MST-16) and merbarone, protect cardiomyocytes from anthracycline toxicity and assessed their effects on anthracycline antineoplastic efficacy. Dexrazoxane and two other TOP2 inhibitors protected isolated neonatal rat cardiomyocytes against toxicity induced by both doxorubicin and daunorubicin. However, none of the TOP2 inhibitors significantly protected cardiomyocytes in a model of hydrogen peroxide-induced oxidative injury. In contrast, the catalytic inhibitors did not compromise the antiproliferative effects of the anthracyclines in the HL-60 leukemic cell line; instead, synergistic interactions were mostly observed. Additionally, anthracycline-induced caspase activation was differentially modulated by the TOP2 inhibitors in cardiac and cancer cells. Whereas dexrazoxane was upon hydrolysis able to significantly chelate intracellular labile iron ions, no such effect was noted for either sobuzoxane or merbarone. In conclusion, our data indicate that dexrazoxane may protect cardiomyocytes via its catalytic TOP2 inhibitory activity rather than iron-chelation activity. The differential expression and/or regulation of TOP2 isoforms in cardiac and cancer cells by catalytic inhibitors may be responsible for the selective modulation of anthracycline action observed. |
| first_indexed | 2024-12-19T22:33:27Z |
| format | Article |
| id | doaj.art-d3e2aa6c14e740eaab40bad8e9df02f9 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-19T22:33:27Z |
| publishDate | 2013-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-d3e2aa6c14e740eaab40bad8e9df02f92022-12-21T20:03:16ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-01810e7667610.1371/journal.pone.0076676Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells.Anna VavrovaHana JansovaEliska MackovaMiloslav MachacekPavlina HaskovaLucie TichotovaMartin SterbaTomas SimunekAnthracyclines (such as doxorubicin or daunorubicin) are among the most effective anticancer drugs, but their usefulness is hampered by the risk of irreversible cardiotoxicity. Dexrazoxane (ICRF-187) is the only clinically approved cardioprotective agent against anthracycline cardiotoxicity. Its activity has traditionally been attributed to the iron-chelating effects of its metabolite with subsequent protection from oxidative stress. However, dexrazoxane is also a catalytic inhibitor of topoisomerase II (TOP2). Therefore, we examined whether dexrazoxane and two other TOP2 catalytic inhibitors, namely sobuzoxane (MST-16) and merbarone, protect cardiomyocytes from anthracycline toxicity and assessed their effects on anthracycline antineoplastic efficacy. Dexrazoxane and two other TOP2 inhibitors protected isolated neonatal rat cardiomyocytes against toxicity induced by both doxorubicin and daunorubicin. However, none of the TOP2 inhibitors significantly protected cardiomyocytes in a model of hydrogen peroxide-induced oxidative injury. In contrast, the catalytic inhibitors did not compromise the antiproliferative effects of the anthracyclines in the HL-60 leukemic cell line; instead, synergistic interactions were mostly observed. Additionally, anthracycline-induced caspase activation was differentially modulated by the TOP2 inhibitors in cardiac and cancer cells. Whereas dexrazoxane was upon hydrolysis able to significantly chelate intracellular labile iron ions, no such effect was noted for either sobuzoxane or merbarone. In conclusion, our data indicate that dexrazoxane may protect cardiomyocytes via its catalytic TOP2 inhibitory activity rather than iron-chelation activity. The differential expression and/or regulation of TOP2 isoforms in cardiac and cancer cells by catalytic inhibitors may be responsible for the selective modulation of anthracycline action observed.http://europepmc.org/articles/PMC3792022?pdf=render |
| spellingShingle | Anna Vavrova Hana Jansova Eliska Mackova Miloslav Machacek Pavlina Haskova Lucie Tichotova Martin Sterba Tomas Simunek Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells. PLoS ONE |
| title | Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells. |
| title_full | Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells. |
| title_fullStr | Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells. |
| title_full_unstemmed | Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells. |
| title_short | Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells. |
| title_sort | catalytic inhibitors of topoisomerase ii differently modulate the toxicity of anthracyclines in cardiac and cancer cells |
| url | http://europepmc.org/articles/PMC3792022?pdf=render |
| work_keys_str_mv | AT annavavrova catalyticinhibitorsoftopoisomeraseiidifferentlymodulatethetoxicityofanthracyclinesincardiacandcancercells AT hanajansova catalyticinhibitorsoftopoisomeraseiidifferentlymodulatethetoxicityofanthracyclinesincardiacandcancercells AT eliskamackova catalyticinhibitorsoftopoisomeraseiidifferentlymodulatethetoxicityofanthracyclinesincardiacandcancercells AT miloslavmachacek catalyticinhibitorsoftopoisomeraseiidifferentlymodulatethetoxicityofanthracyclinesincardiacandcancercells AT pavlinahaskova catalyticinhibitorsoftopoisomeraseiidifferentlymodulatethetoxicityofanthracyclinesincardiacandcancercells AT lucietichotova catalyticinhibitorsoftopoisomeraseiidifferentlymodulatethetoxicityofanthracyclinesincardiacandcancercells AT martinsterba catalyticinhibitorsoftopoisomeraseiidifferentlymodulatethetoxicityofanthracyclinesincardiacandcancercells AT tomassimunek catalyticinhibitorsoftopoisomeraseiidifferentlymodulatethetoxicityofanthracyclinesincardiacandcancercells |